IE901736L - Polypeptide-antibody conjugate for inhibiting cell adhesion - Google Patents

Polypeptide-antibody conjugate for inhibiting cell adhesion

Info

Publication number
IE901736L
IE901736L IE901736A IE173690A IE901736L IE 901736 L IE901736 L IE 901736L IE 901736 A IE901736 A IE 901736A IE 173690 A IE173690 A IE 173690A IE 901736 L IE901736 L IE 901736L
Authority
IE
Ireland
Prior art keywords
polypeptide
cell adhesion
antibody conjugate
inhibiting cell
disclosed
Prior art date
Application number
IE901736A
Original Assignee
Fuller H B Licensing Financ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuller H B Licensing Financ filed Critical Fuller H B Licensing Financ
Publication of IE901736L publication Critical patent/IE901736L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A polypeptide-antibody conjugate is disclosed that contains an integrin-binding polypeptide operatively attached to an antibody molecule that immunoreacts with adhesitory cell surface antigens. Therapeutic compositions and methods using those compositions are also disclosed whereby the polypeptide-antibody conjugate can be used to inhibit cell adhesion and cell adhesion-dependent processes such as tumor growth and platelet aggregation. [WO9014103A1]
IE901736A 1989-05-17 1990-05-14 Polypeptide-antibody conjugate for inhibiting cell adhesion IE901736L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36261789A 1989-05-17 1989-05-17

Publications (1)

Publication Number Publication Date
IE901736L true IE901736L (en) 1990-11-17

Family

ID=23426812

Family Applications (1)

Application Number Title Priority Date Filing Date
IE901736A IE901736L (en) 1989-05-17 1990-05-14 Polypeptide-antibody conjugate for inhibiting cell adhesion

Country Status (6)

Country Link
AU (1) AU5815990A (en)
CA (1) CA2016962A1 (en)
GR (1) GR900100372A (en)
IE (1) IE901736L (en)
PT (1) PT94067A (en)
WO (1) WO1990014103A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
JP3283041B2 (en) * 1990-07-13 2002-05-20 学校法人藤田学園 Artificial antibody
CA2109332A1 (en) * 1991-05-03 1992-11-04 Elaine Tuomanen Antibody recognizing endothelial cell ligand for leukocyte cr3
WO1994009034A1 (en) * 1992-10-12 1994-04-28 Agen Limited Clot directed anticoagulant, process for making same and methods of use
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
JP2001522817A (en) * 1997-11-07 2001-11-20 コンジュケム，インコーポレーテッド Novel conjugate of opioid and endogenous carrier
BR0014222A (en) * 1999-09-23 2003-02-25 Scripps Research Inst Method and compositions for inhibiting adhesion formation
CN1230441C (en) 2000-04-12 2005-12-07 安盛药业有限公司 Integrin binding peptide derivatives
NO20004795D0 (en) 2000-09-26 2000-09-26 Nycomed Imaging As Peptide-based compounds
WO2003006491A2 (en) 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
US20110256055A1 (en) 2008-12-23 2011-10-20 Ge Healthcare Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
US9035028B2 (en) 2010-03-10 2015-05-19 Emory University Temperature sensitive conjugate compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
WO1983003971A1 (en) * 1982-05-12 1983-11-24 President And Fellows Of Harvard College Hybrid proteins

Also Published As

Publication number Publication date
CA2016962A1 (en) 1990-11-17
PT94067A (en) 1991-02-08
GR900100372A (en) 1991-10-10
AU5815990A (en) 1990-12-18
WO1990014103A1 (en) 1990-11-29

Similar Documents

Publication Publication Date Title
IE901736L (en) Polypeptide-antibody conjugate for inhibiting cell adhesion
USD279651S (en) Combined container and closure
CA2102301A1 (en) Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
CA2017025A1 (en) Tumor necrosis factor binding protein ii, its purification and antibodies thereto
AU549204B2 (en) Intravenously injectable immune serum globulin
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU3066489A (en) Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
AU591774B2 (en) Lysine salt of the gadolinium-dota complex and its applications to diagnosis
AU2460988A (en) Simultaneous immunoassay for the determination of antigens and antibodies
AU519091B2 (en) Protein concentrate containing immunological factors of lactic origin
AU3533689A (en) Tight binding of proteins to surfaces
EP0212403A3 (en) Monoclonal antibodies to mucin-like human differentiation antigens
AU3847589A (en) Procedure and container for the preparation and storage of platelet concentrates
USD261231S (en) Bottle or similar article
EP0212807A3 (en) Coloured compound containing a cationic group and a reactive group
AU3040589A (en) Homoarginine-based peptides as platelet aggregation inhibitors
AU567747B2 (en) Early detection of mammalian pregnancy
AU550364B2 (en) Immunogen of lidocaine-protein conjugate and antibodies derived therefrom
IL82930A (en) Antibodies for the detection of mammalian carcinomas and their preparation
AU2493184A (en) Specific cea-family antigens, antibodies specific thereto and their methods of use
AU5359586A (en) Brain derivable polypeptide factors and antibodies
AU7912887A (en) Monoclonal antibodies to fibrin
CA2106563A1 (en) Cocaine derivatives and protein and polypeptide cocaine derivative conjugates and labels
GR860229B (en) Monoclonal antibody against a ras oncogene p21 relatied dodecapeptide
USD284935S (en) Planting pot clamp for suspended supports